UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
Stocks · News reference
Teva Says Topline Results From Ongoing Phase 2a Study Of TEV ‘408 For Celiac Disease Met Its Primary Endpoint, Demonstrating Statistically Significant And Clinically Meaningful Prevention Of Gluten-induced Intestinal Damage Versus Placebo At Week 8
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from an ongoing Phase 2a study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.
Teva Stock Rises After TEV '408 Meets Primary Endpoint in Celiac Disease Study
Teva Pharma is trading higher after announcing positive topline results from a Phase 2a study of TEV '408, which met its primary endpoint.
Teva Pharmaceutical Industries shares are trading higher after the company announced topline results from an ongoing Phase 2a study of TEV ‘408. The study met its primary endpoint.